Researchers who have plateaued on dual agonists are exploring whether the switch from tirzepatide to retatrutide provides another level of receptor novelty and metabolic activation
Market perspective Fast-track approval reflects urgency in tackling obesity Oral therapies may capture ~20% of the market by 2030 Expands access for patients preferring pills over injections While Novo Nordisk may offer slightly higher weight loss with its oral option, ease of use and flexibility position this therapy as a strong competitor
Pro-inflammatory cytokines from activation of microglia can lead to the formation of A1 astrocytes, which are implicated in the pathogenesis of glaucoma and have diminished ability to phagocytose and poorer synapse support [96, 97]
Weight loss from GLP-1s may ease those symptoms and support healthier testosterone levels through better rest
If you are working with a 10 mg vial, or planning to, this is the reference you will return to repeatedly
Adipose tissue dysfunction as determinant of obesity-associated metabolic complications
